Cadila Healthcare Ltd has received approval from the US FDA to market Warfarin tablets in different strengths of 1 mg, 2 mg, 2.5 mg, 3 mg, 4mg, 5mg 6mg, 7.5 mg and 10 mg.
The group plans to launch the product within a month's time. The branded sales of the product in 2005 were reported to be over $ 210 million. With this, the group now has a total of 14 approvals.
The group is likely to have considerable competitive advantage in this product as it will be sourcing the API from its own US FDA approved manufacturing facility at Dabhasa. The drug, an anti-coagulant, falls in the cardiovascular segment.